Carboxy-terminal telopeptide (CTX) and amino-terminal propeptide (PINP) of type i collagen as markers of bone metastases in patients with non-small cell lung cancer

Anticancer Research

Volumn 33, Issue 6, 2013, Pages 2593-2596

  Lumachi, Franco ^a   Santeufemia, Davide A ^b   Del Conte, Alessandro ^b   Mazza, Francesco ^b   Tozzoli, Renato ^b   Chiara, Giordano B ^b   Basso, Stefano M M ^b  

^a UNIVERSITY OF PADOVA   (Italy)

^b S MARIA DEGLI ANGELI HOSPITAL   (Italy)

Author keywords

Bone metastasis; CEA; CTX; CYFRA 21 1; Lung cancer; NSCLC; PINP; TRAP5b

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; AMINO TERMINAL TELOPEPTIDE; BIOLOGICAL MARKER; CARBOXY TERMINAL TELOPEPTIDE; CARCINOEMBRYONIC ANTIGEN; CYTOKERATIN 19 FRAGMENT; FLUORODEOXYGLUCOSE F 18; COLLAGEN TYPE 1; COLLAGEN TYPE I TRIMERIC CROSS LINKED PEPTIDE; COLLAGEN TYPE I TRIMERIC CROSS-LINKED PEPTIDE; CYTOKERATIN 19; N PROPEPTIDE TYPE I COLLAGEN; N-PROPEPTIDE TYPE I COLLAGEN; OLIGOPEPTIDE; PEPTIDE; PHOSPHOPEPTIDE; PROCOLLAGEN; TUMOR MARKER;

ADULT; AGED; BONE METASTASIS; BONE REMODELING; BONE SCINTISCANNING; CANCER PATIENT; CLINICAL ARTICLE; CONFERENCE PAPER; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; EARLY DIAGNOSIS; FEMALE; FOLLOW UP; HUMAN; LUNG NON SMALL CELL CANCER; MALE; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SENSITIVITY AND SPECIFICITY; ARTICLE; BONE TUMOR; CTX; LUNG CANCER; LUNG TUMOR; METABOLISM; METASTASIS; MIDDLE AGED; NSCLC; PATHOLOGY; PINP; TRAP5B;

BONE METASTASIS; CEA; CTX; CYFRA 21-1; LUNG CANCER; NSCLC; PINP; TRAP5B;

AGED; BONE NEOPLASMS; CARCINOEMBRYONIC ANTIGEN; CARCINOMA, NON-SMALL-CELL LUNG; COLLAGEN TYPE I; FEMALE; HUMANS; KERATIN-19; LUNG NEOPLASMS; MALE; MIDDLE AGED; OLIGOPEPTIDES; PEPTIDES; PHOSPHOPEPTIDES; PROCOLLAGEN; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

MLCS; MLOWN;

EID: 84881348652     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (32)

1. Siegel R, Naishadham D and Jemal A: Cancer statistics, 2012. CA Cancer J Clin 62: 10-29, 2012.
2. Mery CM, Pappas AN, Bueno R, Colson YL, Linden P, Sugarbaker DJ and Jaklitsch MT: Similar long-term survival of elderly patients with non-small cell lung cancer treated with lobectomy or wedge resection within the Surveillance, Epidemiology, and End Results database. Chest 128: 237-245, 2005.
3. Hur J, Lee HJ, Nam JE, Kim YJ, Hong YJ, Kim HY, Kim SK, Chang J, Kim JH, Chung KY, Lee HS and Choi BW: Additional diagnostic value of tumor markers in cytological fluid for diagnosis of non-small-cell lung cancer. BMC Cancer 12: 392, 2012.
4. Sekine I, Sumi M and Saijo N: Local control of regional and metastatic lesions and indication for systemic chemotherapy in patients with non-small cell lung cancer. Oncologist 13(Suppl 1): 21-27, 2008.
5. Vansteenkiste J, Vandebroek J, Nackaerts K, Dooms C, Galdermans D, Bosquee L, Delobbe A, Deschepper K, Van Kerckhoven W, Vandeurzen K, Deman R, D'Odemont JP, Siemons L, Van den Brande P and Dams N: Influence of cisplatin-use, age, performance status and duration of chemotherapy on symptom control in advanced non-small cell lung cancer: Detailed symptom analysis of a randomised study comparing cisplatin-vindesine to gemcitabine. Lung Cancer 40: 191-199, 2003.
6. Lumachi F, Brunello A, Roma A and Basso U: Cancer-induced hypercalcemia. Anticancer Res 29: 1551-1555, 2009.
7. Kurata T and Nakagawa K: Efficacy and safety of denosumab for the treatment of bone metastases in patients with advanced cancer. Jpn J Clin Oncol 42: 663-669, 2012.
8. Brown JE, Cook RJ, Major P, Lipton A, Saad F, Smith M, Lee KA, Zheng M, Hei YJ and Coleman RE: Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst 97: 59-69, 2005.
9. Lumachi F, Marino F, Orlando R, Chiara GB and Basso SMM: Simultaneous multianalyte immunoassay measurement of five serum tumor markers in detection of colorectal cancer. Anticancer Res 32: 985-988, 2012.
10. Muley T, Dienemann H and Ebert W: CYFRA 21-1 and CEA are independent prognostic factors in 153 operated stage I NSCLC patients. Anticancer Res 24: 1953-1956, 2004.
11. Cedres S, Nunez I, Longo M, Martinez P, Checa E, Torrejon D and Felip E: Serum tumor markers CEA, CYFRA21-1, and CA-125 are associated with worse prognosis in advanced non-small cell lung cancer (NSCLC). Clin Lung Cancer 12: 172-179, 2011.
12. Matsuoka K, Sumitomo S, Nakashima N, Nakajima D and Misaki N: Prognostic value of carcinoembryonic antigen and CYFRA21-1 in patients with pathological stage I non-small cell lung cancer. Eur J Cardiothorac Surg 32: 435-439, 2007.
13. Washino S, Hirai M, Matsuzaki A and Kobayashi Y: Clinical usefulness of CEA, CA19-9, and CYFRA 21-1 as tumor markers for urothelial bladder carcinoma. Urol Int 87: 420-428, 2011.
14. Muley T, Fetz TH, Dienemann H, Hoffmann H, Herth FJ, Meister M and Ebert W: Tumor volume and tumor marker index based on CYFRA 21-1 and CEA are strong prognostic factors in operated early stage NSCLC. Lung Cancer 60: 408-415, 2008.
15. Anglim PP, Alonzo TA and Laird-Offringa IA: DNA methylation-based biomarkers for early detection of non-small cell lung cancer: An update. Mol Cancer 7: 81, 2008.
16. Bae HM, Lee SH, Kim TM, Kim DW, Yang SC, Wu HG, Kim YW and Heo DS: Prognostic factors for non-small cell lung cancer with bone metastasis at the time of diagnosis. Lung Cancer 77: 572-577, 2012.
17. Cuaron J, Dunphy M and Rimner A: Role of FDG-PET scans in staging, response assessment, and follow-up care for non-small cell lung cancer. Front Oncol 2: 208, 2012.
18. Komissarova M, Wong KK and Fig LM: (18)F-FDG PET/CT and (99m)Tc-MDP imaging of non-small cell lung carcinoma osseous metastases. J Nucl Med Technol 40: 66-67, 2012.
19. Yao NS, Wu YY, Janckila AJ, Ku CH, Hsieh AT, Ho CL, Lee SH and Chao TY: Serum tartrate-resistant acid phosphatase 5b (TRACP5b) activity as a biomarker for bone metastasis in nonsmall cell lung cancer patients. Clin Chim Acta 412: 181-185, 2011.
20. Sivolella S, Lumachi F, Stellini E and Favero L: Denosumab and anti-Angiogenic drug-related osteonecrosis of the jaw: An uncommon but potentially severe disease. Anticancer Res 33: 1793-1798, 2013.
21. Luftner D, Jozereau D, Schildhauer S, Geppert R, Muller C, Fiolka G, Wernecke KD and Possinger K: PINP as serum marker of metastatic spread to the bone in breast cancer patients. Anticancer Res 25: 1491-1499, 2005.
22. Wisłowska M, Jakubicz D, Stepień K and Cicha M: Serum concentrations of formation (PINP) and resorption (CTX) bone turnover markers in rheumatoid arthritis. Rheumatol Int 29: 1403-1409, 2009.
23. Tanishi N, Yamagiwa H, Hayami T, Mera H, Koga Y, Omori G and Endo N: Relationship between radiological knee osteoarthritis and biochemical markers of cartilage and bone degradation (urine CTX-II and NTX-I): the Matsudai Knee Osteoarthritis Survey. J Bone Miner Metab 27: 605-612, 2009.
24. Shidara K, Inaba M, Okuno S, Yamada S, Kumeda Y, Imanishi Y, Yamakawa T, Ishimura E and Nishizawa Y: Serum levels of TRAP5b, a new bone resorption marker unaffected by renal dysfunction, as a useful marker of cortical bone loss in hemodialysis patients. Calcif Tissue Int 82: 278-287, 2008.
25. Halleen JM: Tartrate-resistant acid phosphatase 5B is a specific and sensitive marker of bone resorption. Anticancer Res 23: 1027-1029, 2003.
26. Lumachi F, Camozzi V, Doretto P, Tozzoli R and Basso SM: Circulating PTH, vitamin D and IGF-I levels in relation to bone mineral density in elderly women. In Vivo 27: 415-418, 2013.
27. Koizumi M, Takahashi S and Ogata E: Comparison of serum bone resorption markers in the diagnosis of skeletal metastasis. Anticancer Res 23: 4095-4099, 2003.
28. Kong QQ, Sun TW, Dou QY, Li F, Tang Q, Pei FX, Tu CQ and Chen ZQ: Beta-CTX and ICTP act as indicators of skeletal metastasis status in male patients with non-small cell lung cancer. Int J Biol Markers 22: 214-220, 2007.
29. Tamiya M, Suzuki H, Kobayashi M, Sasada S, Okamoto N, Morishita N, Yasue T, Matsuura Y, Hirashima T and Kawase I: Usefulness of the serum cross-linked N-telopeptide of type I collagen as a marker of bone metastasis from lung cancer. Med Oncol 29: 215-218, 2012.
30. Lumachi F, Marino F, Fanti G, Chiara GB and Basso SM: Serum N-telopeptide of type I collagen and bone alkaline phosphatase and their relationship in patients with non-small cell lung carcinoma and bone metastases. Preliminary results. Anticancer Res 31: 3879-3881, 2011.
31. Terpos E, Kiagia M, Karapanagiotou EM, Charpidou A, Dilana KD, Nasothimiou E, Harrington KJ, Polyzos A and Syrigos KN: The clinical significance of serum markers of bone turnover in NSCLC patients: Surveillance, management and prognostic implications. Anticancer Res 29: 1651-1657, 2009.
32. Chao TY, Wu YY and Janckila AJ: Tartrate-resistant acid phosphatase isoform 5b (TRACP 5b) as a serum maker for cancer with bone metastasis. Clin Chem Acta 411: 1553-1564, 2010.